GleamWall
中文EN

PLSE PULSE BIOSCIENCES, INC.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1625101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,637.2%
TTM net income YoY-12.0%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin26.8%
Operating margin-5,821.1%
Net margin-5,603.9%
FCF margin-4,263.9%
EBITDA margin-5,796.8%

Returns

ROE-60.6%
ROA-54.0%
ROIC (approx.)-95.2%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets8.9%
Debt / equity0.00x
Current ratio14.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue24.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$395,000$434,000$401,000$264,000$86,000$0$0$0
Cost of revenue$191,000$273,000$370,000$260,000$279,000$0$0$0
Gross profit$204,000$161,000$31,000$4,000-$193,000$0$0$0
R&D expense$16.85M$16.98M$12.59M$10.93M$11.39M$12.09M$10.31M$10.66M
SG&A expense$7.65M$8.46M$6.59M$7.33M$8.78M$8.19M$7.73M$9.60M
Operating income-$24.29M-$25.27M-$19.15M-$18.25M-$20.37M-$20.27M-$18.04M-$20.26M
Pretax income—————-$19.17M-$16.80M-$19.39M
Income tax—————$0$0$0
Net income-$23.05M-$24.66M-$18.58M-$17.43M-$19.39M-$19.17M-$16.80M-$19.39M
EBITDA-$24.20M-$25.18M-$19.06M-$18.16M-$20.27M-$20.18M-$17.93M-$20.14M
EPS (basic)-0.32-0.36-0.27—-0.29-0.28-0.25—
EPS (diluted)————————
Balance sheet
Cash & equivalents$36.73M$101.62M$68.32M$80.73M$95.21M$106.35M$119.28M$118.04M
Receivables$297,000$122,000$157,000$274,000$15,000——$0
Inventory$232,000$236,000$206,000$136,000$57,000$51,000$30,000$0
Current assets$192.21M$105.70M$71.13M$83.42M$97.16M$108.16M$120.91M$119.45M
PP&E, net$1.07M$1.06M$1.02M$1.05M$1.05M$1.11M$1.06M$1.16M
Goodwill$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M$2.79M
Intangibles$55,000$222,000$408,000$575,000$741,000$907,000$1.05M$1.22M
Total assets$201.58M$115.56M$81.62M$94.54M$108.77M$120.25M$133.38M$132.46M
Current liabilities$13.39M$10.98M$9.80M$7.92M$9.70M$8.98M$7.76M$10.05M
Total liabilities$18.01M$16.06M$15.32M$13.88M$16.07M$15.76M$14.93M$17.60M
Shareholders' equity$183.57M$99.50M$66.30M$80.66M$92.69M$104.49M$118.45M$114.86M
Shares outstanding73.31M70.80M68.23M67.84M67.74M67.28M67.27M65.93M
Cash flow statement
Operating cash flow-$15.27M-$18.71M-$14.60M-$14.76M-$13.04M-$12.81M-$13.52M-$9.14M
Capital expenditure$142,000$90,000$33,000$105,000$62,000$103,000$45,000$53,000
Free cash flow-$15.41M-$18.80M-$14.63M-$14.86M-$13.10M-$12.91M-$13.57M-$9.20M
Investing cash flow-$152.49M-$90,000-$33,000-$105,000-$62,000-$123,000-$45,000-$53,000
Financing cash flow$102.87M$52.10M$2.21M$381,000$1.97M$0$14.81M$48.20M
Depreciation & amortization$94,000$88,000$88,000$93,000$100,000$100,000$117,000$121,000
Stock-based compensation$5.31M$4.97M$1.91M$4.97M$5.62M$5.19M$5.68M$6.79M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.